Strong sales acceleration of QUVIVIQ drives Idorsia toward profitability – H1 2025 results
Ad hoc announcement pursuant to Art. 53 LR QUVIVIQ™ (daridorexant): Strong performance and sales acceleration with total net sales of CHF 58 million in H1 2025 and increase of 145% compared